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It has been difficult to reconcile the absence of pathology and apparently normal behavior of mice lacking prion protein (PrP), referred to as
Prnp0/0 mice, with a mechanism of prion pathogenesis involving progressive loss of PrPC-mediated neuroprotection. However, here we report that
Prnp0/0 mice exhibit significant age-related defects in motor coordination and balance compared with mice expressing wild type Prnp on a
syngeneic background, and that the brains of behaviorally-impaired Prnp0/0 mice display the cardinal neuropathological hallmarks of spongiform
pathology and reactive astrocytic gliosis that normally accompany prion disease. Consistent with the appearance of cerebellar ataxia as an early
symptom in patients with Gerstmann–Sträussler–Scheinker syndrome (GSS), an inherited form of human prion disease, motor coordination and
balance defects manifested in a transgenic (Tg) mouse model of GSS considerably earlier than the onset of end-stage neurodegenerative disease.
Our results are consistent with a mechanism in which loss of normal PrPC function is an important pathological component of prion diseases.
© 2007 Elsevier B.V. All rights reserved.Keywords: Prion; Spongiform degeneration; PrPC neuroprotection1. Introduction
The precursor–product relationship between the cellular and
disease-associated forms of PrP, referred to as PrPC and PrPSc
respectively, is well established for prion replication. In
contrast, the mechanism by which prions elicit brain damage
and the relative contributions of PrPSc accumulation and PrPC
depletion to this process remain unclear. Prion disorders are
generally viewed as gain-of-function diseases with neuronal
damage resulting from the accumulation of PrPSc. However,
certain examples of natural and experimental prion disease
occur without accumulation of detectable protease resistant
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doi:10.1016/j.bbadis.2007.04.004equivalent to the time course of PrPSc accumulation in mice
expressing lower than normal levels of PrPC [5]. Moreover,
grafting experiments of PrPC-expressing neuroectodermal
tissue into Prnp0/0 mouse brains convincingly demonstrated
that PrPSc is not toxic to cells that do not express PrPC, even
after long-term exposure [6].
While the prion resistant phenotype of Prnp0/0 mice and
their inability to replicate infectivity [5,7,8] is in accordance
with the prion hypothesis, Prnp0/0 mice have not been as
definitive in resolving the physiological and possible patholog-
ical functions of PrPC. Because the gene encoding PrP is highly
conserved among species and is ubiquitously expressed, it was
anticipated that Prnp0/0 mice would display overt phenotypic
deficits that would provide information about essential
physiological functions of PrPC. In contrast to expectations,
initial studies of Prnp0/0 mice produced in Zurich and
Edinburgh indicated that they developed and behaved normally
[9,10]. While Prnp0/0 mice subsequently produced in Nagasaki
developed a progressive ataxia and Purkinje cell degeneration at
∼70 weeks of age [11], these defects were found to be the result
Fig. 1. Longitudinal analysis of motor and balance coordination of wild type
FVB and Prnp0/0 mice on the rotarod. Groups of 8 age-matched wild type FVB
mice (filled squares) and Prnp0/0 mice (open squares) were subjected to rotarod
behaviour analysis as described. Each mouse was tested three independent times
on each test date. The mean latency to falling ±SEM was recorded for mice in
each group on each date. Significant differences (p value b 0.05) between the
mean performances of mice of different genotypes at each time point was
established using an unpaired, two-tailed t-test with asterisks indicating the
degree of significance between genotypes.
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protein, Doppel (Dpl), in the central nervous system (CNS)
[12,13].
While subtle phenotypic defects in the Zurich and Edinburgh
Prnp0/0 knockout mouse strains suggested roles for PrPC in
maintaining normal circadian rhythms [14], superoxide dis-
mutase activity and protection from oxidative stress [15] and
copper metabolism [16], the lack of overt phenotypic deficits
raised the possibility that adaptive developmental changes might
compensate for loss of PrPC function in Prnp0/0 mice. Arguing
against this possibility, Tgmice in which expression of PrPC was
suppressed in adult mice using a tetracycline-responsive trans-
activator [17], or mice in which neuronal PrP was post-natally
ablated [18], remained free of any abnormal phenotype.
Other lines of evidence contend that PrPC provides cellular
protective functions, raising the possibility that their disruption
features in prion pathogenesis. Hippocampal cells from Prnp0/0
mice were more sensitive than cells derived from wild-type mice
to serumwithdrawal-induced apoptosis, an effect rescued by PrPC
or Bcl-2 [19], and cerebellar cells from Prnp0/0 mice were more
sensitive to oxidative stress [20]. Also, overexpression of PrPC
rescued Bax-induced cell death in primary human neurons [21]. A
growing body of evidence suggests that cell surface-anchored
PrPC may provide a neuroprotective signaling function [22,23]
raising the possibility that impairment of this function is a feature
of prion pathogenesis. Consistent with this notion, Tg mice ex-
pressing non-membrane tethered PrP, while they replicate prions
and accumulate PrPSc, do not develop clinical prion disease [24].
A neuroprotective role for PrPC raises the possibility that loss
of normal PrPC function in the brains of patients expressing
mutant PRNP alleles is a component of the pathology of inher-
ited prion disorders [25]. GSS is one example of an autosomal
dominant inherited prion disease in humans. A common form of
GSS is linked to a missense mutation resulting in replacement of
proline to leucine at codon 102, referred to as P102L. The
clinical and neuropathological features of GSS have been
reproduced in Tg mice overexpressing a mouse PrP gene with
the corresponding mutation at codon 101 (P101L), referred to as
Tg(GSS) mice [4,26,27].
Herewe show that Tgmice expressing null ormissensemutant
Prnp alleles exhibit an age-dependent motor behavior deficit
suggesting a function for PrPC in maintaining sensorimotor
coordination. We also report that the brains of Prnp0/0 mice
exhibit region-specific spongiform degeneration and reactive
astrocytic gliosis which are neuropathological hallmarks of prion
diseases. Impairment of sensorimotor function in Tg(GSS) mice
prior to the onset of end-stage neurodegenerative disease suggests
that loss of PrPC function is an early feature of prion pathogenesis.
2. Materials and methods
2.1. Transgenic mice
The Zurich strain ofPrnp0/0mice, whichwere originallymaintained on amixed
129/Sv and C57BL/6 genetic background, were subsequently repeatedly crossed
with wild-type FVB animals to produce FVB/Prnp0/0 mice [28]. Breeding pairs
were obtained from Stanley Prusiner by way of George Carlson at the McLaughlin
Research Institute, Great Falls,Montana, and an inbred colony was established andmaintained at the University of Kentucky. The production and characterization of
Tg(GSS)22mice, which were originally produced on anFVB/Prnp0/0 background,
has been described previously [4]. The Tg(GSS)22 line, which is homozygous for
the MoPrP-P101L transgene, was also maintained an FVB/Prnp0/0 background.
2.2. Determination of spontaneous prion disease
Groups of mice were monitored thrice weekly for the development of prion
disease. The date of disease was recorded as the age at onset of progressive
clinical symptoms of prion disease including truncal ataxia, hind-limb paresis,
loss of extensor reflex and tail stiffening.
2.3. Histopathologic analysis
Animals whose death was obviously imminent were euthanized and their
brains taken for histopathological studies. Brains were dissected rapidly after
sacrifice of the animal and immersion fixed in 10% buffered formalin. Tissues
were embedded in paraffin and 10 μm thick coronal microtome sections were
mounted onto positively charged glass slides and stained with hematoxylin and
eosin for evaluation of spongiform degeneration. Following inactivation of
endogenous peroxidases by incubation in 3% H2O2 in methanol, peroxidase
immunohistochemistry was used to evaluate the extent of reactive astrocytic
gliosis using antibodies to glial fibrillary acidic protein. Detection was with
Vectastain ABC reagents and slides were developed with diaminobenzidine.
2.4. Semi-automated lesion profiling
Paraffin-embedded mouse brains were sectioned coronally to areas cor-
responding to the five levels of the brain that contained the 16 mouse brain regions
of interest. Brain sections were stained with hematoxylin and eosin. Images of the
each of the 16 brain regions were captured using a Photometrics Cool Snap digital
camera and a Nikon Eclipse E600 microscope. Each image was processed using
Metamorph (Universal Imaging Corporation) version 6.2r6 software. The thresh-
olding feature of this program was used to differentiate vacuoles from irrelevant
background objects. Once a threshold was reached that maximized detection of true
647K.E. Nazor et al. / Biochimica et Biophysica Acta 1772 (2007) 645–653vacuoles, the software-processed vacuoles were measured usingMetamorph's auto-
trace region tool which automatically delineates well-defined vacuole edges, records
the area of each vacuole and integrates the number of vacuoles per field. Lesion
density, the number of vacuoles per field, was plotted on the y-axis with the
corresponding brain region on the x-axis using Prism GraphPad Prism 4 Software.
Error bars represent the average number of vacuoles per field ± SEM in the brains of
three age-matched mice per genotype.
2.5. Behavioral testing
Rotarod testing was performed on groups of eight age-matched Tg(GSS)22,
wild type FVB, FVB/Prnp0/0mice using a Dual Species Economex Rotarodmodel
#0207-003M (Columbus Instruments) Testing was initiated when mice were
60 days of age. Mice were tested within a conserved ∼3 h time period in the
morning. Mice were trained for 3 consecutive days prior to the first official testing
date by repeatedly placing the mice on the rod until they were able to remain on a
rod rotating at a constant speed of 5 r.p.m./s. for 90 s. In both training and official
testing, during the first trial of the day, mice were placed on the stationary rod and
allowed to become familiar with the environment for 1 min before the rod motor
was engaged. On each testing day, each mouse was tested for three trials with a 10-
min inter-trial resting period. For each consecutive trail, mice were allowed toFig. 2. Histopathological profiles of Prnp0/0 and wild type FVB mouse brains Usin
neuronal vacuolation in 16 different brain regions shown in A. Images are adapted
collosum; 2: anterior midline cerebral cortex; 3: primary motor cortex; 4: para termina
level of the hippocampus; 8: hippocampus; 9: thalamus; 10: medial globus pallidus; 11
medulla; 16: inferior cerebellar peduncle and trigeminal tract. (B) The mean (±SEM)
FVB mice (solid bars) or three age-matched (at 6 months) Prnp0/0 mice (open bars) a
score in each brain region was established using an unpaired, two-tailed t-test withbecome acquainted with the environment for 30 s. For testing, the rod motor was
initially set at 5 r.p.m. with an acceleration rate of 0.3 r.p.m./s for a maximum trial
period of 180 s and performance was measured as latency to fall in seconds.3. Results
3.1. Sensorimotordeficits are associatedwith loss of PrP function
To evaluate whether loss of PrP function affected coordination
and balance in Prnp0/0 mice we assessed performance on the
Rotarod, a well-characterized behavioral task designed to assess
motor function by requiring mice to ambulate on an accelerating
rotating rod, with latency to fall as a measure of motor function.
While there were no significant differences between the
performances of young wild type FVB mice and Prnp0/0 mice
that, apart from thePrnp nullmutation, were otherwise syngeneic,
after 95 days of agePrnp0/0mice remained on the accelerating rod
for an average of ∼50% less time than wild type FVB mice overg a semi-automated modification of the lesion profiling system we quantified
(with permission) from [46]. Regions are as follows: 1: forceps minor corpus
l body; 5: striatum; 6: posterior midline cerebral cortex; 7: corpus collosum at the
: hypothalamus; 12: tectum (midbrain); 13: midbrain; 14: cerebellum; 15: dorsal
number of vacuoles per field in each of 16 regions of the brains of three wild type
re shown. Significant differences (p valueb0.05) between the mean vacuolation
asterisks indicating the degree of significance between genotypes.
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performance between Prnp0/0 and wild type FVB mice during
this time were highly significant (Fig. 1).
3.2. Neuronal vacuolar degeneration in Prnp0/0/FVB mice
Microscopic examination of the CNS of patients or animals
with prion disease typically reveals a characteristic triad of his-
topathological changes consisting of neuronal vacuolation andFig. 3. Spongiform degeneration and astrocytic gliosis in the brains ofPrnp0/0mice The ex
wild type FVB mice was determined in hematoxylin and eosin stained brain sections, w
astrocytic gliosis using antibodies to glial fibrillary acidic protein (GFAP). (A–D) Hem
through the medial globus pallidus (region 10) and cerebellum (region 14) of Prnp0/0 an
medial globus pallidus of wild type FVB mice; (C and G) Cerebellum of Prnp0/0 mice;degeneration, which confers a microvacuolated or ‘spongiform’
appearance, and a reactive proliferation of glial cells. To assess
whether the sensorimotor deficits we detected in older Prnp0/0
mice correlated with the presence of neuropathological lesions
normally associated with prion disease, we assessed the
histopathological profiles of multiple brain sections from
Prnp0/0 mice and age-matched wild type FVB mice. To analyze
vacuolar degeneration, we developed a semi-automated mod-
ification of the lesion profiling system developed by Fraser andtent of spongiform degeneration in the brains ofPrnp0/0 and age-matched (6months)
hile peroxidase immunohistochemistry was used to evaluate the extent of reactive
atoxylin and eosin staining, (E–H) GFAP immunohistochemistry of brain sections
d wild type FVB mice. (A and E) Medial globus pallidus of Prnp0/0 mice; B and F:
(D and H) Cerebellum of wild type FVB mice. Bar =100 μm.
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brain regions (Fig. 2A). Surprisingly, significant and reproduc-
ible spongiform pathology was present in the brains of Prnp0/0/
FVB mice at 6 months of age (Fig. 2). Vacuolar lesion profiling
showed that the corpus collosum at the level of the
hippocampus (region 7), the medial globus pallidus (region
10), the cerebellum (region 14), and the inferior cerebellar
peduncle and spinal trigeminal tract (region 16) were
particularly affected regions in Prnp0/0 mice (Fig. 2B).
Representative examples of spongiform degeneration and
coincident reactive astrocytic gliosis in the brains of Prnp0/0
mice at the level of the medial globus pallidus and cerebellum
are shown in Fig. 3.
3.3. Sensorimotor deficits precede the onset of spontaneous
neurodegeneration in Tg(GSS) mice
The neuromotor deficits and prion disease-related neuropa-
thology in aged mice expressing a null Prnp allele suggests that
loss of normal PrPC function is an important pathological com-Fig. 4. Sensorimotor deficits precede the spontaneous onset of neurodegenerative dis
Tg(GSS)22 mice were subjected to rotarod behaviour analysis as described. Each m
falling ±SEMwas recorded for mice in each group on each date. Filled squares signify
(GSS)22mice. Significant differences (Pb0.05) between the mean performances of
t-test with asterisks indicating the degree of significance between genotypes. (B) Sp
Tg(GSS)22 mice; filled squares signify the performance of wild type FVB mice, non
with previous results [27], spontaneous disease did not occur in Tg(MoPrP)4112 m
(n=5 mice).ponent of prion disease and raises the possibility that progressive
loss of PrPC function contributes to the pathogenesis of inherited
prion diseases. To investigate whether motor behavioral impair-
ments also occurred in mice expressing a missense Prnp allele,
we evaluated the performances of Tg(GSS) mice of different ages
and age-matched wild type FVB mice on the accelerating rotarod
(Fig. 4A). Consistent with previous reports [4], all Tg(GSS)22
mice overexpressing mutant mouse PrP-P101L, spontaneously
developed a progressive neurological disorder with a mean age of
onset of 163±8 days (±standard error of the mean, n=7) (Fig.
4B). However, sensorimotor deficits manifested considerably
earlier than the onset of these neurological symptoms. Significant
impairments of motor coordination and balance in Tg(GSS)22
mice were detected as early as 60 days of age, which was 70 days
earlier than the time at which the first Tg(GSS)22 mice
spontaneously developed neurological signs, and N100 days
earlier than the mean age of spontaneous disease in Tg(GSS)
mice. The performance of Tg(GSS)22 mice on the rotarod
progressively deteriorated. After 95 days of age, extreme deficits
in rotarod performance were consistently observed in Tg(GSS)22ease in Tg(GSS)22 mice. (A) Groups of 8 age-matched wild type FVB mice and
ouse was tested three independent times on each test date. The mean latency to
the performance of FVB mice, while open circles signify the performance of Tg
mice of different genotypes at each time point was established using an unpaired
ontaneous neurodegenerative disease in Tg(GSS)22 mice. Open circles signify
e of which (n=8) developed disease in the same time frame; and, in accordance
ice overexpressing wild type mouse PrP (open squares) up to 590 days of age
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disease, at which point the ataxic phenotype made it impossible
for Tg(GSS)22 mice to remain on the rod. As a result of the
sensorimotor deficits in Prnp0/0 mice, the differences in
performance between Tg(GSS)22 and Prnp0/0 mice did not
become significant until mice were 123 days of age which was
only 1 week before the first Tg(GSS)22 mice spontaneously
developed neurologic signs, and 40 days earlier than themean age
of spontaneous disease.
3.4. Kinetics of vacuolar degeneration parallel PrPSc
accumulation in the brains of Tg(GSS) mice
Previous studies using the PrPSc-specific monoclonal
antibody (Mab) 15B3, showed that, while the levels of total
MoPrP-P101L in the brains of Tg(GSS)22 mice remained
constant as mice aged, substantial quantities of the pathological
form of MoPrP-P101L accumulated immediately prior to the
onset of clinical symptoms [4]. We were therefore interested to
ascertain whether the development of neuropathological lesionsFig. 5. Kinetics and regional distribution of spongiform degeneration in the brain
spontaneously sick Tg(GSS)22 mice was determined in hematoxylin and eosin stained
pathology (A: cerebellum— region 14), or consistently high amounts of spongiform
peroxidase immunohistochemistry was used to evaluate the extent of reactive astrocy
fibrillary acidic protein. (D) Neuronal vacuolation was quantified in 16 different brain
6 months of age; black symbols: 5 months of age; magenta symbols: 4 months of age;
1 month of age.in the brains of aging Tg(GSS)22 mice followed similar
kinetics.
Coincident with the accumulation of mutant MoPrPSc-P101L
in the brains of sick Tg(GSS)22 mice, the appearance of severe
spongiform degeneration and accompanying reactive astrocytic
gliosis was abrupt and did not appear until the end stage of disease
when Tg(GSS)22 mice displayed an overt clinical phenotype. The
most profoundly affected brain regions, with more than 150
vacuoles occupying each observation field, were the primary
motor cortex (region 3), striatum (region 5), the posterior mid-line
of the cerebral cortex (region 6), and the corpus collosum at the
level of the hippocampus (region 7) (Fig. 5 ). While vacuolation in
the inferior cerebellar peduncle and spinal trigeminal tract (region
16) was relatively modest, lesions appeared earlier in this region
and the degeneration was progressive.
4. Discussion
Initial behavioral tests of the Zurich Prnp0/0 mice, including
swimming navigation, Y-Maze discrimination and the two-ways of Tg(GSS)22 mice The extent of spongiform degeneration in the brains of
brain sections. For comparison, regions are shown where little or no spongiform
pathology (B: posterior midline cerebral cortex— region 6 was detected. In C,
tic gliosis in the posterior midline cerebral cortex region using antibodies to glial
regions of (see Fig. 2 legend) Tg(GSS)22 mice of different ages. Blue symbols:
green symbols: 3 months of age; red symbols: 2 months of age; orange symbols:
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pression did not compromise learning ability [9]. Subsequent
studies of learning and memory and associated hippocampal
function using Prnp0/0 knockout mice have provided variable
results [31–34]. Electrophysiological studies suggesting that
GABAA receptor-mediated fast inhibition and long-term poten-
tiation were impaired in hippocampal slices from Zurich Prnp0/0
mice [35,36] were not independently confirmed [28,37]. While
progressive cognitive dysfunction is a feature of prion diseases in
humans, physical problems such as ataxia, and changes in gait and
posture are also typical characteristics. Therefore, in our
behavioral assessments we used rotarod performance which
requires postural adjustments for the maintenance of equilibrium
on a rotating and accelerating rod. Rotarod performance is a
commonly used task to assess motor coordination in genetically
and pharmacologically modified mouse models and, while the
ability to perform the rotarod task cannot be attributed to a single
brain region, it has been shown to be a sensitive indicator of
cerebellar abnormalities, for example in Lurcher mice [38].While
retinal degeneration in FVB mice caused by Pde6b gene
mutations preclude tests of cognitive behavior that depend on
vision, sight-impaired inbred mouse strains, including FVB,
perform on the accelerating rotarod as well as strains that are not
visually impaired, and FVB mice have been extensively used in
rotarod studies [39,40].
Cerebellar ataxia is an early symptom of GSS, preceding
the onset of progressive dementia, and in some cases the
clinical phase of disease may be as long as 10 years. The
occurrence of sensorimotor deficits in Tg(GSS) mice similar
to those observed in Prnp0/0 mice but considerably earlier
than the onset of end-stage neurodegeneration is consistent
with a mechanism involving progressive loss of mutant PrPC
function. In patients with inherited prion diseases such as
GSS, loss of PrP function is presumably exacerbated at later
times by the dominant-negative effects of mutant PrPSc.
Indeed, our previous studies demonstrated that MoPrPSc-
P101L accelerates prion disease in Tg(GSS) mice and that its
accumulation is a late event in the course of disease [4]. Our
studies suggest that the early behavioral abnormalities in Tg
(GSS) mice serve as a preclinical predictor of prion disease
that may be suitable for use in preclinical drug testing. Such
approaches have been successfully applied using Tg models
of Huntington's disease (HD) [41,42] which exhibit behav-
ioral anomalies as early as 3 to 4 weeks of age.
Our results raise the question of why the neuropathological
deficits reported here were not previously detected in Prnp0/0
mice. Seminal studies indicated coarse vacuolation in the
Ammons horn of the hippocampus in about one third of
Zurich Prnp0/0 or wild type mice analyzed [9]. Interestingly,
histopathological analysis of older Zurich Prnp0/0 mice at 33
or 57 weeks post-inoculation with the Chandler prion isolate
lacked vacuolation or gliosis in the molecular and pyramidal
layers of the telencephalitic cortex or the ventromedial
thalamic nucleus [7]. In other studies, scrapie-specific
neuropathology was not detected in the brains of Prnp0/0
mice ∼500 days post-inoculation with mouse adapted RML
scrapie prions [43].While the original Zurich strain of Prnp0/0 mice were
maintained on a mixed 129/Sv and C57BL/6 genetic
background, the Prnp0/0 mice used in these studies were
derived by repeated crossing with wild-type FVB animals
[28]. The resulting Prnp0/0 mice were used for the generation
of Tg mice because of the large pronuclei and breeding
performance of the FVB strain. In the current studies we
compared mice expressing wild type and mutant Prnp alleles
on syngeneic FVB/NJ (FVB) backgrounds. Our results raise
the possibility that additional genetic factors may influence
the development of spongiform degeneration; it may therefore
be of considerable interest to assess the effect of the Prnp
disruption in a variety different of inbred backgrounds.
Interestingly, deficiencies in other genes, notably Mahogunin
in Attractin (formerly mahogany) result in similar age-
dependent spongiform neurodegeneration but without accu-
mulation of PrPSc [44,45]. Both mahoganoid and Atrn
mutations affect coat color similar to Agouti. To explain the
phenotypic overlap in Mahogunin and Attractin deficiencies,
He and colleagues proposed a model in which neuronal
accumulation of an unknown substrate(s) which is normally
targeted for proteosomal degradation resulting from the E3
ubiquitin ligase activity of Mahogunin, results in progressive
vacuolation, astrocytosis, and neuronal cell death [45]. While
PrP is not ubiquitinated by Mahogunin, our results raise the
intriguing possibility that PrP, Atrn and Mahogunin function
in the same pathway to preserve neuronal viability.
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